Under the European CSRD directive and ESRS standards, sustainability reporting is no longer optional. At the core lies double materiality – a dual perspective that changes how we think about impact:
How your company affects the environment and society
How sustainability factors affect your business performance
For pharma companies, this is more than compliance. It is a strategic opportunity to:
Build trust with stakeholders
Focus on what truly matters
Drive long-term value
Double materiality is not just regulation – it is the foundation for a sustainable future.
